AVE 0.00% 0.3¢ avecho biotechnology limited

half-year financials, page-33

  1. 34,916 Posts.
    lightbulb Created with Sketch. 480
    ..with respect mak,i'm sick of your posts,and financials being the reason for our crappy sp...


    turps, not putting a gun to your head, just ignore my posts if you find them so abhorrent. I'm simply presenting the facts and basing an opinion, you don't have to agree with it. If you think a 40% drop in revenue has had no bearing on the share price then good for you. Give your reasons and let others make judgement.

    Me I thinkt he share price has dropped as we suspected due to ppor financials. The theories presented prior to last night's announcement now seem to have been backed up by the results.

    How'd the rerun go?

    how much is in the bank,and what do we need to realise our objective?

    Around $20mill give or take was my understanding. And Phase 3 hasn't started yet. No doubt there has been extra expense due to the delay and new development arrangement. It's not rocket science. As it stands now there will not be enough money to take Phase 3 through to completion. Of course things can quickly change and there are other deals that may come to fruition. However as we have seen with Elixia over the last few years, it takes time for those deals to grow into meaningful revenues.
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
(20min delay)
Last
0.3¢
Change
0.000(0.00%)
Mkt cap ! $9.507M
Open High Low Value Volume
0.3¢ 0.3¢ 0.3¢ $4.366K 1.455M

Buyers (Bids)

No. Vol. Price($)
62 90468113 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 60283238 17
View Market Depth
Last trade - 15.51pm 26/07/2024 (20 minute delay) ?
AVE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.